Patents by Inventor Peter A. Virsik

Peter A. Virsik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF
    Publication number: 20240051926
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 15, 2024
    Inventors: Han-Jie ZHOU, Peter Virsik
  • ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG
    Publication number: 20240024249
    Abstract: Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed.
    Type: Application
    Filed: June 13, 2023
    Publication date: January 25, 2024
    Inventors: Sarina Grace Harris MA, Laura Elizabeth BAUER, Sami KARABORNI, David J. WUSTROW, Peter A. VIRSIK
  • ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20230373934
    Abstract: The present invention relates to compounds of formula (ABC), (BC), (A), (B), (B-I), (C), (C-I), (D), (D-I), (E), (E-I), (F), (G), (H), (J), or (K), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer, including prostate cancer.
    Type: Application
    Filed: April 24, 2023
    Publication date: November 23, 2023
    Inventors: Han-Jie ZHOU, Peter VIRSIK, Berenger BIANNIC
  • Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
    Patent number: 11814357
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Grant
    Filed: December 5, 2022
    Date of Patent: November 14, 2023
    Assignee: ESSA Pharma Inc.
    Inventors: Han-Jie Zhou, Peter Virsik
  • SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF
    Publication number: 20230104598
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Application
    Filed: December 5, 2022
    Publication date: April 6, 2023
    Inventors: Han-Jie ZHOU, Peter VIRSIK
  • Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
    Patent number: 11518747
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: December 6, 2022
    Assignee: ESSA Pharma, Inc.
    Inventors: Han-Jie Zhou, Peter Virsik
  • ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20220380378
    Abstract: The present invention relates to compounds of formula (A), (A-I), (A-II), (A-III), (B), (B-I), (C), (D), (E), (E-I), (F), (G), (H), (J), and (K), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer, including prostate cancer.
    Type: Application
    Filed: April 22, 2022
    Publication date: December 1, 2022
    Inventors: Han-Jie ZHOU, Peter Virsik, Berenger Biannic
  • ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20220380325
    Abstract: The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.
    Type: Application
    Filed: June 30, 2021
    Publication date: December 1, 2022
    Inventors: Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar
  • Androgen receptor modulators and methods for their use
    Patent number: 11485713
    Abstract: Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: November 1, 2022
    Assignees: ESSA Pharma, Inc., The University of British Columbia, Provincial Health Services Authority
    Inventors: Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Daniel Andrew Golec
  • SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF
    Publication number: 20220259158
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Application
    Filed: April 28, 2022
    Publication date: August 18, 2022
    Inventors: Han-Jie Zhou, Peter Virsik
  • PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF
    Publication number: 20220218632
    Abstract: The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor N-terminal domain inhibitor or an inhibitor and a second therapeutically active agent, such as an CDK4/6 inhibitor, a Pin1 inhibitor (inhibitor of peptidyl-prolyl cis/trans isomerases), or an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer. Further, the present disclosure relates administering an androgen receptor N-terminal domain inhibitor in combination with radiation therapy for treatment of various cancers.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 14, 2022
    Inventors: Peter Virsik, Han-Jie Zhou, Marianne Dorothy Sadar, Raymond John Andersen, Kunzhong Jain, Daniel Andrew Golec
  • PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF
    Publication number: 20220202780
    Abstract: The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor modulator or an inhibitor and a second therapeutically active agent, such as an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 30, 2022
    Inventors: Peter Virsik, Han-Jie Zhou, Ronan Le Moigne
  • Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
    Patent number: 11358938
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: June 14, 2022
    Assignee: ESSA Pharma, Inc.
    Inventors: Han-Jie Zhou, Peter Virsik
  • PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF
    Publication number: 20220105093
    Abstract: The present disclosure generally relates to pharmaceutical compositions and combinations comprising N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy) methyl)pyrimidin-2-yOmethanesulfonamideN-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl) propan-2-yl) phenoxy) methyl)pyrimidin-2-yl)methanesulfonamide or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, and a second therapeutically active agent, such as an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer.
    Type: Application
    Filed: September 16, 2021
    Publication date: April 7, 2022
    Inventors: Peter Virsik, Han-Jie Zhou
  • SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF
    Publication number: 20220073472
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Application
    Filed: November 15, 2021
    Publication date: March 10, 2022
    Inventors: Han-Jie Zhou, Peter Virsik
  • Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof
    Patent number: 11242324
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: February 8, 2022
    Assignee: ESSA Pharma, Inc.
    Inventors: Han-Jie Zhou, Peter Virsik
  • SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF
    Publication number: 20210332016
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Application
    Filed: June 9, 2021
    Publication date: October 28, 2021
    Inventors: Han-Jie Zhou, Peter Virsik
  • SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF
    Publication number: 20210323931
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Application
    Filed: April 16, 2021
    Publication date: October 21, 2021
    Inventors: Han-Jie Zhou, Peter Virsik
  • Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
    Publication number: 20210228525
    Abstract: Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
    Type: Application
    Filed: February 3, 2021
    Publication date: July 29, 2021
    Inventors: Kenneth C. Cundy, Sami Karaborni, Peter A. Virsik
  • Androgen receptor modulators and methods for their use
    Patent number: 11059795
    Abstract: The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: July 13, 2021
    Assignees: ESSA Pharma, Inc., The University of British Columbia, Provincial Health Services Authority
    Inventors: Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar